Related papers: Multimodal Neuroimaging Attention-Based architectu…
Alzheimer's Disease (AD) is a progressive neurodegenerative disease. Amnestic mild cognitive impairment (MCI) is a common first symptom before the conversion to clinical impairment where the individual becomes unable to perform activities…
Structural MRI and PET imaging play an important role in the diagnosis of Alzheimer's disease (AD), showing the morphological changes and glucose metabolism changes in the brain respectively. The manifestations in the brain image of some…
For effective treatment of Alzheimer disease (AD), it is important to identify subjects who are most likely to exhibit rapid cognitive decline. Herein, we developed a novel framework based on a deep convolutional neural network which can…
Unveiling pathological brain changes associated with Alzheimer's disease (AD) is a challenging task especially that people do not show symptoms of dementia until it is late. Over the past years, neuroimaging techniques paved the way for…
Multi-modal biological, imaging, and neuropsychological markers have demonstrated promising performance for distinguishing Alzheimer's disease (AD) patients from cognitively normal elders. However, it remains difficult to early predict when…
Alzheimer's Disease (AD) is one of the most concerned neurodegenerative diseases. In the last decade, studies on AD diagnosis attached great significance to artificial intelligence (AI)-based diagnostic algorithms. Among the diverse…
Alzheimer's disease (AD) is the most common age-related dementia. Mild cognitive impairment (MCI) is the early stage of cognitive decline before AD. It is crucial to predict the MCI-to-AD conversion for precise management, which remains…
Purpose: This study investigates whether a machine-learning-based system can predict the rate of cognitive decline in mildly cognitively impaired patients by processing only the clinical and imaging data collected at the initial visit.…
Multimodal neuroimaging provides complementary structural and functional insights into both human brain organization and disease-related dynamics. Recent studies demonstrate enhanced diagnostic sensitivity for Alzheimer's disease (AD)…
Alzheimer's disease (AD) is a neurodegenerative disorder that affects more than seven million people in the United States alone. AD currently has no cure, but there are ways to potentially slow its progression if caught early enough. In…
Alzheimer's Disease (AD) is a non-curable progressive neurodegenerative disorder that affects the human brain, leading to a decline in memory, cognitive abilities, and eventually, the ability to carry out daily tasks. Manual diagnosis of…
Alzheimer's disease (AD) is a prevalent neurodegenerative disorder that progressively impairs memory, decision-making, and overall cognitive function. As AD is irreversible, early prediction is critical for timely intervention and…
In the last decade, computer-aided early diagnostics of Alzheimer's Disease (AD) and its prodromal form, Mild Cognitive Impairment (MCI), has been the subject of extensive research. Some recent studies have shown promising results in the AD…
Alzheimer's Disease (AD) is an irreversible neurodegenerative disease characterized by progressive cognitive decline as its main symptom. In the research field of deep learning-assisted diagnosis of AD, traditional convolutional neural…
Computer-aided early diagnosis of Alzheimer's disease (AD) and its prodromal form mild cognitive impairment (MCI) based on structure Magnetic Resonance Imaging (sMRI) has provided a cost-effective and objective way for early prevention and…
A common neurodegenerative disease, Alzheimer's disease requires a precise diagnosis and efficient treatment, particularly in light of escalating healthcare expenses and the expanding use of artificial intelligence in medical diagnostics.…
Nowadays, a lot of scientific efforts are concentrated on the diagnosis of Alzheimer's Disease (AD) applying deep learning methods to neuroimaging data. Even for 2017, there were published more than a hundred papers dedicated to AD…
The aging population of the U.S. drives the prevalence of Alzheimer's disease. Brookmeyer et al. forecasts approximately 15 million Americans will have either clinical AD or mild cognitive impairment by 2060. In response to this urgent…
Predicting whether subjects with mild cognitive impairment (MCI) will convert to Alzheimer's disease is a significant clinical challenge. Longitudinal variations and complementary information inherent in longitudinal and multimodal data are…
Objectives: The objectives of this narrative review are to summarize the current state of AI applications in neuroimaging for early Alzheimer's disease (AD) prediction and to highlight the potential of AI techniques in improving early AD…